Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jutta L. Miller"'
Autor:
Keith Gottesdiener, Jutta L. Miller, Thomas Marbury, Nancy G. B. Agrawal, Paul F. Cavanaugh, David Hoelscher, Jules I. Schwartz, Kenneth Bachmann, Peggy H. Wong
Publikováno v:
The Journal of Clinical Pharmacology. 49:1202-1209
The authors designed 2 randomized controlled studies to examine the effects of etoricoxib 60 to 120 mg daily on methotrexate pharmacokinetics in 50 rheumatoid arthritis (RA) patients on stable doses of methotrexate (7.5-20 mg). Patients received oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65754b447f1e89c887f738e82b264bf6
https://doi.org/10.1177/0091270009338939
https://doi.org/10.1177/0091270009338939
Autor:
Jutta L. Miller, Thomas Marbury, Gregory A. Winchell, Keith Gottesdiener, G. Mistry, John A. Wagner, Prasad P. Kari, Richard C. Simpson, A. David Rodrigues
Publikováno v:
The Journal of Clinical Pharmacology. 45:699-703
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0962662fb267351faf0b3ec5f9ae780
https://doi.org/10.1177/0091270005275289
https://doi.org/10.1177/0091270005275289
Autor:
Arturo G. Porras, Jutta L. Miller, David L. Ebel, J. S. Redfern, Gregory B. Holmes, Nancy G. B. Agrawal, Marshall Sack, Jules I. Schwartz, Barry J. Gertz, Kenneth Bachmann, Peggy H. Wong
Publikováno v:
The Journal of Clinical Pharmacology. 41:1120-1130
Rofecoxib is a highly selective and potent inhibitor of cyclooxgenase-2 (COX-2). Methotrexate is a disease-modifying agent with a narrow therapeutic index frequently prescribed for the management of rheumatoid arthritis. The objective of this study w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe6782e756422f01f0c919bd916bb13e
https://doi.org/10.1177/00912700122012616
https://doi.org/10.1177/00912700122012616
Autor:
Katelijn, Decochez, Ronda K, Rippley, Jutta L, Miller, Marina, De Smet, Kerri X, Yan, Zissi, Matthijs, Kerry A, Riffel, Hengchang, Song, Haiyuan, Zhu, Hannah O, Maynor, Wesley, Tanaka, Amy O, Johnson-Levonas, Michael J, Davies, Keith M, Gottesdiener, Bart, Keymeulen, John A, Wagner
Publikováno v:
Drugs in RD. 7(2)
The objective of these studies was to evaluate the pharmacokinetics and pharmacodynamics of MK-0767, a prototypical dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, following administration of single and multiple oral doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c159a5b96925e7d58739f456172eba8e
https://pubmed.ncbi.nlm.nih.gov/16542056
https://pubmed.ncbi.nlm.nih.gov/16542056